LEADERSHIP

Developed and Optimized a CRISPR/Cas9-based gene editing system in hematopoietic stem cells when studied at Harvard and worked at BRL Medicine.

Led the world’s first CRISPR/Cas9 Gene editing clinical trial for patients with β0/β0 thalassemia in 2020. Two pediatric patients with β-thalassemia achieved transfusion independence following treatment in three years.

Professor at East China Normal University Co-founder, VP at BRL Medicine Postdoc at Harvard Medical School, Associate Professor at CASPhD (Biology) at Wuhan University.

Published gene editing articles in top journals: Nature Medicine (x3), Cell Stem Cell (x3), and Cell Research.

Non-Viral Delivery Systems, in-vivo Gene Editing, Product Development, CMC.

10 years+ biotech and pharma industry experience in product development, screen, optimization of mRNA-lipid nanoparticle (LNP)-based drug products to preclinical POC, IND-Enabling, Phase I/II for gene editing programs, led the development of highly potent liver and extrahepatic delivery systems.

Ph.D(Chemistry) at Max Planck Institute.

B. & M.Eng at McGill University.

Gene Editing Technology Development and Platform Operation.

10 years+ experience in gene editing and base editing technology, successfully developed various gene editing methods with 6 patents.

Founder of BIOGLE Gene (CRO of Gene Editing).

PI of Shanghai Jiao Tong University.

Ph. D at Wuhan University.

IN/OUT License, Strategic Partnership, Equity Deals.

15+ years pharmaceutical industry experience in business development, alliance management, marketing and investment in top multinational companies and biotech.

PhD candidate in Montpellier university, received a master's degree in biomedicine from the China Academy of Science and a MBA degree in CEIBS.